Get the Stockscreener App
4.09
0.99%
0.04
After Hours:
4.14
0.05
+1.22%
Sana Biotechnology Inc stock is traded at $4.09, with a volume of 5.46M.
It is up +0.99% in the last 24 hours and down -0.73% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
See More
Previous Close:
$4.05
Open:
$3.91
24h Volume:
5.46M
Relative Volume:
0.99
Market Cap:
$972.63M
Revenue:
-
Net Income/Loss:
$-252.18M
P/E Ratio:
-3.8585
EPS:
-1.06
Net Cash Flow:
$-185.29M
1W Performance:
-17.37%
1M Performance:
-0.73%
6M Performance:
+140.59%
1Y Performance:
+31.94%
1-Day Range:
$3.65
$4.18
1-Week Range:
$3.65
$5.00
52-Week Range:
$1.26
$7.30
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
4.09 | 1.04B | 0 | -252.18M | -185.29M | -1.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Wedbush | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Applying big data sentiment scoring on Sana Biotechnology Inc.Quarterly Trade Report & Low Volatility Stock Recommendations - newser.com
Will Sana Biotechnology Inc. stock benefit from automationQuarterly Earnings Report & Expert Curated Trade Ideas - newser.com
Identifying reversal signals in Sana Biotechnology Inc.2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com
Why Sana Biotechnology Inc. stock is a must watch in 20252025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Sana: Q3 Earnings Snapshot - theheraldreview.com
Sana Biotechnology Makes Bold Bet On Diabetes And Gene Therapy - Finimize
Sana Biotechnology Reports Reduced Losses and Strong Liquidity - TipRanks
Decoding Sana Biotechnology Inc (SANA): A Strategic SWOT Insight - GuruFocus
Will Sana Biotechnology Inc. stock maintain momentum in 20252025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Sana Biotechnology Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Sana Biotechnology Q3 net loss narrows - MarketScreener
Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates - The Manila Times
BRIEF-Sana Biotechnology Q3 Operating Expenses USD 43.515 Million - TradingView
Published on: 2025-11-06 09:37:46 - newser.com
Is Sana Biotechnology Inc. stock a smart buy before Fed meetingTrade Volume Report & Low Risk High Win Rate Stock Picks - newser.com
Can Sana Biotechnology Inc. recover in the next quarter2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com
Using Ichimoku Cloud for Sana Biotechnology Inc. technicals2025 Market WrapUp & Weekly High Return Stock Forecasts - newser.com
Visual trend scoring systems applied to Sana Biotechnology Inc.2025 Geopolitical Influence & Stepwise Swing Trade Plans - newser.com
Is Sana Biotechnology Inc. stock overvalued by current metricsTake Profit & Verified Technical Signals - fcp.pa.gov.br
Long term hold vs stop loss in Sana Biotechnology Inc.July 2025 EndofMonth & Intraday High Probability Alerts - newser.com
What indicators show strength in Sana Biotechnology Inc.Fed Meeting & Fast Gain Stock Trading Tips - newser.com
What makes Sana Biotechnology Inc. stock attractive to growth funds2025 Price Action Summary & Verified Chart Pattern Signals - fcp.pa.gov.br
How Sana Biotechnology Inc. stock benefits from global expansionWeekly Trading Summary & Weekly Breakout Opportunity Watchlist - fcp.pa.gov.br
What MACD signals say about Sana Biotechnology Inc.July 2025 PreEarnings & Intraday High Probability Setup Alerts - newser.com
Earnings visualization tools for Sana Biotechnology Inc.Market Activity Report & Smart Swing Trading Techniques - newser.com
Custom strategy builders for tracking Sana Biotechnology Inc.July 2025 Pullbacks & Expert Verified Movement Alerts - newser.com
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit - The Manila Times
Using economic indicators to assess Sana Biotechnology Inc. potential2025 Key Lessons & AI Forecasted Entry and Exit Points - newser.com
Published on: 2025-11-04 00:42:20 - newser.com
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):